Meghan Trainor, Maintenance, and What Happens If You Stop

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for Meghan Trainor, Maintenance, and What Happens If You Stop

At a glance

  • Public record: Meghan Trainor has described her weight loss as the result of diet, exercise, and lifestyle changes in public interviews.
  • GLP-1 status: Publicly speculated by media outlets; not confirmed by Trainor or any representative.
  • Clinical focus: What peer-reviewed data show about weight regain after stopping GLP-1 receptor agonists, and what maintenance strategies have evidence behind them.
  • Why it matters: When a high-visibility public figure loses weight, health-information-seeking behavior spikes. Understanding the clinical reality behind the drug class being speculated about is a direct public health service.

What Meghan Trainor Has Actually Said

Meghan Trainor, the Grammy-winning artist known in part for body-positive anthems like "All About That Bass," has been visibly slimmer in public appearances over the past several years. In interviews with People magazine and elsewhere, she has credited her physical changes to intentional lifestyle work, including attention to nutrition, activity, and her mental relationship with food. She has described walking regularly, working with fitness professionals, and making sustainable dietary adjustments.

At no point has Trainor publicly confirmed using semaglutide, tirzepatide, liraglutide, or any other GLP-1 receptor agonist. Media speculation has circulated widely, as it has for dozens of public figures in recent years, but speculation is not confirmation. The HealthRX Medical Team treats this distinction as non-negotiable.

What makes Trainor's public story worth clinical attention is not what she may or may not be taking privately. It is the pattern her story fits into: a high-profile individual loses meaningful weight, attributes it to lifestyle, and is immediately subject to public debate about pharmaceutical assistance. That debate, playing out in millions of social media comments and search queries, reflects genuine public confusion about how GLP-1 medications work, how durable their effects are, and what "stopping" actually means for the body.

GLP-1 Receptor Agonists: A Brief Mechanistic Primer

GLP-1 (glucagon-like peptide-1) receptor agonists mimic the incretin hormone GLP-1, which is released from intestinal L-cells in response to food. The drugs bind GLP-1 receptors in the pancreas, gut, and brain, producing a coordinated set of effects: increased insulin secretion, suppressed glucagon release, slowed gastric emptying, and, critically for weight management, reduced appetite and increased satiety signaling in the hypothalamus.

Semaglutide (brand names Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) are currently the dominant agents in this class for weight management. Semaglutide at 2.4 mg weekly produced mean weight loss of approximately 14.9% of body weight over 68 weeks in the STEP 1 trial, compared with 2.4% with placebo. Tirzepatide produced even larger effects in the SURMOUNT-1 trial, with the highest dose group achieving mean weight loss of 22.5% of body weight.

These are not trivial numbers. They represent a class of medication that, for many patients, produces weight loss previously achievable only through bariatric surgery.

The Discontinuation Problem: What the Data Actually Show

Here is where the clinical picture becomes uncomfortable, and where the public conversation around celebrity weight loss stories often falls apart.

GLP-1 receptor agonists appear to work primarily while you are taking them. The STEP 1 extension trial, published in Diabetes, Obesity and Metabolism, followed participants who completed 68 weeks of semaglutide treatment and then stopped. One year after discontinuation, participants had regained approximately two-thirds of the weight they had lost. Cardiometabolic improvements, including reductions in waist circumference, blood pressure, and glycemic markers, also largely reversed.

The tirzepatide story is similar. Data from the SURMOUNT-4 trial, published in JAMA, showed that participants who switched from tirzepatide to placebo after 36 weeks of treatment regained 14 percentage points of body weight over the subsequent 52 weeks, while those who continued tirzepatide lost an additional 5.5%.

The HealthRX Medical Team's read on this data is direct: for most patients, GLP-1 therapy functions more like a long-term medication for a chronic condition than a finite course of treatment. The underlying biology, specifically the appetite dysregulation and metabolic adaptation that characterizes obesity, does not permanently correct after a period of drug exposure. When the pharmacological signal stops, the physiology tends to reassert itself.

This is not a failure of willpower. Research published in the New England Journal of Medicine and subsequent work has demonstrated that significant weight loss triggers compensatory hormonal responses, including persistent elevations in ghrelin and reductions in leptin and peptide YY, that actively drive the body toward its prior weight. GLP-1 agonists suppress these signals pharmacologically. Remove the drug, and the signals return.

What "Lifestyle Maintenance" Can and Cannot Do

If Trainor's weight loss is, as she states, primarily attributable to lifestyle changes, what does the evidence say about lifestyle-based maintenance after significant weight loss?

The short answer is that lifestyle interventions alone are genuinely effective for a subset of patients, and genuinely insufficient for most. The National Weight Control Registry, which tracks individuals who have maintained meaningful weight loss long-term, identifies consistent patterns: high levels of physical activity (averaging around 60 minutes per day), regular dietary monitoring, consistent meal patterns, and ongoing self-monitoring of weight. These are real behaviors with real evidence behind them.

The harder clinical reality is that population-level data from the Look AHEAD trial and meta-analyses of behavioral weight loss programs show that most people regain the majority of lost weight within three to five years of completing a lifestyle intervention, even with continued support. The body's compensatory physiology is powerful.

This does not mean lifestyle change is worthless. It means that for individuals whose weight loss involves GLP-1 pharmacotherapy, discontinuing the medication while expecting lifestyle changes to hold all the gains is a strategy that requires realistic expectations and close medical monitoring.

Dose Tapering vs. Abrupt Discontinuation

Clinically, there is an important distinction between abrupt GLP-1 discontinuation and structured tapering. No strong randomized trial has yet established a superior tapering protocol for preserving weight loss after stopping. Current FDA prescribing information for Wegovy does not specify a mandatory taper for discontinuation, in contrast to some other drug classes.

Some clinicians advocate for dose reduction over several weeks to soften the rebound in appetite. The physiological rationale is plausible, since abrupt removal of appetite suppression may produce a sharper compensatory hunger response than gradual withdrawal. But the evidence base for tapering as a weight-preservation strategy specifically remains limited, and the HealthRX Medical Team recommends patients have this conversation with their prescribing physician rather than self-directing a taper.

What is clear from the literature is that discontinuation decisions should not be made in isolation from a broader maintenance plan. A 2023 review in Obesity Reviews outlined several considerations for post-GLP-1 maintenance, including continued behavioral support, consideration of lower-dose continuation, and monitoring for the cardiometabolic changes that accompany weight regain.

The Broader Public Health Angle

The reason Meghan Trainor's story matters clinically, even without confirmed GLP-1 use, is precisely the speculation dynamic. When a visible public figure loses weight and GLP-1s are immediately assumed, it sends two simultaneous and contradictory messages to the public: first, that GLP-1s are so effective they must be behind any meaningful weight loss; and second, that celebrity-level results are easily achievable and easily stopped.

Both messages are clinically problematic. The first erases the genuine, documented capacity of intensive lifestyle change to produce meaningful weight loss in motivated individuals. The second dramatically undersells the chronic-disease framing that obesity medicine increasingly uses to describe conditions requiring GLP-1 therapy.

The Endocrine Society's 2023 clinical practice guidelines explicitly frame obesity as a chronic, relapsing disease, recommending that pharmacotherapy, when initiated, be considered a long-term intervention rather than a short-course treatment. The American Diabetes Association's Standards of Care similarly emphasize durable pharmacological management for patients where GLP-1s are indicated.

The HealthRX Medical Team's position: the clinical conversation about any individual's weight management should be private, thorough, and evidence-based. The public conversation, prompted by celebrity visibility, is an opportunity to deliver accurate information about what this drug class does and does not do, regardless of who is or is not using it.

Clinical Considerations If You Are Evaluating Discontinuation

For readers who are themselves on GLP-1 therapy and considering stopping, the evidence supports a few concrete points.

Weight regain after discontinuation is the statistical expectation, not an exception. Planning for it is not pessimistic; it is medically accurate. Anyone stopping GLP-1 therapy should have a documented maintenance strategy in place before stopping, ideally developed with a physician or registered dietitian. Physical activity is the single behavioral variable most strongly associated with long-term weight maintenance in the literature. The American Heart Association's 2021 guidance on obesity management emphasizes combined cardiorespiratory and resistance training for weight maintenance specifically. Finally, if weight regain begins after discontinuation, resuming therapy is a clinically legitimate option, not a personal failure. The biology of weight regain after GLP-1 discontinuation is well-characterized and not a reflection of inadequate effort.

Frequently asked questions

›
›
›
›
›

References

  • Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021. https://pubmed.ncbi.nlm.nih.gov/33957124/
  • Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/
  • Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide." Diabetes, Obesity and Metabolism. 2022. https://pubmed.ncbi.nlm.nih.gov/35441470/
  • Aronne LJ, et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity." JAMA. 2024. https://pubmed.ncbi.nlm.nih.gov/38078526/
  • Sumithran P, et al. "Long-term persistence of hormonal adaptations to weight loss." New England Journal of Medicine. 2011. https://www.nejm.org/doi/full/10.1056/NEJMoa1411925
  • Wing RR, Hill JO. "Successful weight loss maintenance." Annual Review of Nutrition. 2001. https://pubmed.ncbi.nlm.nih.gov/10706592/
  • Look AHEAD Research Group. "Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes." New England Journal of Medicine. 2013. https://pubmed.ncbi.nlm.nih.gov/23796131/
  • Bray GA, et al. "Pharmacological management of obesity." Obesity Reviews. 2023. https://pubmed.ncbi.nlm.nih.gov/37349877/
  • FDA. Wegovy (semaglutide) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  • Endocrine Society Clinical Practice Guidelines: Obesity. 2023. https://www.endocrine.org/clinical-practice-guidelines/obesity
  • American Diabetes Association. Standards of Care in Diabetes. https://diabetesjournals.org/care/article/47/Supplement_1/S1/153936
  • Lau DCW, et al. "Obesity management." Circulation. 2021. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001033
  • People Magazine. "Meghan Trainor Lost 60 Pounds Through Healthy Habits." https://people.com/meghan-trainor-lost-60-pounds-healthy-habits-exclusive-8407929